Current And Recent Trends In Fungal Foot Infection Market: Ken Research


According to the study According to the study, ‘Fungal Foot Infections Drug Development Pipeline Review, 2018, The global athlete’s foot treatment market can be segmented based on drug class, route of administration, distribution channel, and region. Based on the drug intake, the entire industry can be divided into oral and topical antifungals. The sale of these drugs takes place via online pharmacies, hospitals and retail pharmacies. The two main divisions in terms of class of drugs are antifungal antibiotics and steroids and some others.

Foot infections of both the skin and nails of the feet are caused by fungi, virus as well as bacteria. Only in case of fungal infection is it visible since virus and bacteria are invisible to the human eye. Fungi are present everywhere in our day to day surroundings. They flourish mostly in dark moist environments attacking the skin and nails of feet especially when the skin is ragged, making it susceptible to invasion. The most typical form of fungal infection is athlete’s foot or Tinea Pedis, its medical name.  Athlete’s foot most commonly affects the skin between the toes or on the bottom of the feet; causing itching, redness and peeling and sometimes a burning sensation as well as blisters. If untreated, the infection can spread to the toenails leading to the Infection of the nails is called onychomycosis (Tinea Unguium).

Onychomycosis can cause pain, discomfort, and disfigurement and may produce serious physical and occupational limitations, as well as reducing quality of life. The most common test for identifying athlete’s foot is the potassium hydroxide (KOH) exam. A doctor scrapes off a small area of infected skin and places it in potassium hydroxide (KOH). The KOH destroys normal cells and leaves the fungal cells untouched so they are easy to see under a microscope.

The treatment of this disease depends upon tree drug classes namely, the azoles (e.g. flucanzole, the echinocandins and amphotericin to cure these diseases. However, these drugs result in limited success. To identify new drugs and antifungals, a team of Whitehead and MIT  scientists recently screened nearly 3000,000 compounds and found INZ -1 to be have the most apparent potential. In 2016, Blueberry Therapeutics raised EUR 3 Million to innovate and research in drug for topical fungal infection therapies and to move them to clinical trials. The investment will lead into development of possible effect cures for onychomycosis and tinea pedis. In humongous market patients have wanted a drug that has the efficiency of oral treatment but without the threats associated with level of toxicity.

Key players operating in the global athlete’s foot (tinea pedis) treatment market are Valeant Pharmaceuticals, Quinnova Pharmaceuticals, Inc., Anacor Pharmaceuticals, Inc., Cardinal Health, Novartis AG, Merck & Co, Inc., Bayer Healthcare LLC, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Medimetriks Pharmaceuticals, Inc., Medicis Pharmaceutical Corporation, and Johnson and Johnson Healthcare.

Recent developments have proven that fungal infections can be cured in a much quicker and efficient manner with least side effects. Huge investments are being made by companies and investment firms to further expand the scope of the research. The fungal foot infection drug development market will grow at an exponential rate.

To know more, click on the link below:

Related Report:

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications



Comments are closed.